中国医药科学杂志欢迎您.   今天是:        
邹丰,彭秀英,曾春风.输尿管软镜钬激光碎石治疗一期单通道经皮肾镜取石术术后残石的疗效及治疗后血尿及不适症状观察[J].中国医药科学,2021,(4):172-175        基金项目:[基金项目] 广东省梅州市科技计划项目(2019B132)
输尿管软镜钬激光碎石治疗一期单通道经皮肾镜取石术术后残石的疗效及治疗后血尿及不适症状观察
Therapeutic efficacy of ureteroscopic holmium laser lithotripsy on residual stones after phaseⅠ single-channel percutaneous nephrolithotomy and observation on hematuria and discomfort symptoms after treatment
  
DOI:
中文关键词:  [关键词] 输尿管软镜钬激光碎石;单通道经皮肾镜取石术;一期术后残石;血尿;不适症状
英文关键词:[Key words] Ureteroscopic holmium laser lithotripsy; Single-channel percutaneous nephrolithotomy; Residual stones after phaseⅠoperation; Hematuria; Discomfort symptom
作者单位
邹丰,彭秀英,曾春风 广东省丰顺县中医院外科,广东丰顺 514300 
摘要点击次数: 18
全文下载次数: 43
中文摘要:
      [摘要] 目的 观察输尿管软镜钬激光碎石治疗一期单通道经皮肾镜取石术(PCNL)术后残石的疗效及治疗后血尿及不适症状分析。 方法 选取丰顺县中医院2019年5月至2020年5月收治的62例一期单通道经皮肾镜取石术术后残石患者,随机分成两组,对照组(n=31)实施再次PCNL 碎石术,试验组(n=31)实施输尿管软镜钬激光碎石治疗。比较术后清石率,主要症状消失情况,住院时间,住院总费用,术后1年内疼痛不适、血尿、感染并发症、结石复发发生情况。 结果 试验组患者术后一期清石率(96.77%)高于对照组(74.19%),试验组患者术后二期清石率(3.23%)低于对照组(25.81%),两组患者主要症状消失时间与住院时间均短于对照组,而住院总费用均少于对照组,差异有统计学意义(P<0.05)。试验组患者术后1年内疼痛不适率(3.23%)低于对照组(22.58%),血尿率(3.23%)低于对照组(19.35%),感染并发症率(10.00%)低于对照组(33.33%),结石复发率(3.23%)低于对照组(22.58%),差异有统计学意义(P<0.05)。 结论 在一期单通道经皮肾镜取石术后残石患者的治疗中,以输尿管软镜钬激光碎石治疗,可明显提升术后清石率,缩短患者主要症状消失时间、住院时间,降低住院费用,降低患者术后1年内的疼痛不适、血尿、感染并发症及结石复发率,效果理想。
英文摘要:
      [Abstract] Objective To observe the therapeutic efficacy of ureteroscopic holmium laser lithotripsy on residual stones after phaseⅠ single-channel percutaneous nephrolithotomy and to analyze the hematuria and discomfort after treatment. Methods A total of 62 patients with residual stones after phaseⅠ single-channel percutaneous nephrolithotomy admitted to Fengshun Hospital of Traditional Chinese Medicine recently from May 2019 to May 2020 were randomly divided into the control group (n=31) and the experimental group (n=31). The control group was treated with PCNL lithotripsy again, while the experimental group was treated with ureteroscopic holmium laser lithotripsy. The stone clearance rate, disappearance time of main symptoms, hospitalization time, total hospitalization expenses, pain and discomfort, hematuria, infection complications as well as relapse of stones within one year after operation were compared. Results The phaseⅠstone clearance rate in the experimental group was 96.77%, higher than 74.19 % in the control group, while the phase Ⅱ stone clearance rate in the experimental group was 3.23 % , lower than 25.81 % in the control group. The disappearance time of main symptoms and hospitalization time of the two groups of patients were both shorter than those in the control group, while the total hospitalization expenses were all lower than that in the control group, with statistically significant differences (P < 0.05). Within one year after operation, the pain and discomfort rate, hematuria rate, incidence of infectious complication and stone relapse rate of the experimental group were 3.23%, 3.23%, 10.00% and 3.23%, lower than 22.58%, 19.35%, 33.33% and 22.58 % , respectively, with statistically significant differences (P < 0.05). Conclusion In the treatment of patients with residual stones after phaseⅠsingle-channel percutaneous nephrolithotomy, ureteroscopic holmium laser
查看全文  查看/发表评论  下载PDF阅读器
关闭
关键词: 中国医药科学 中国医学 中国医学科学 中华医学 医学杂志 临床医学杂志 医学期刊 中国预防医学 中华预防医学 预防医学杂志 中国药学 药学杂志
药理杂志 中国中医 中医杂志 中华中医药 中医药杂志 中国医疗 医疗器械杂志 中国中西医结合 中国医药 医药杂志 医药期刊 医药论文 医学论文 科研论文 职称论文
function PdfOpen(url){ var win="toolbar=no,location=no,directories=no,status=yes,menubar=yes,scrollbars=yes,resizable=yes"; window.open(url,"",win); } function openWin(url,w,h){ var win="toolbar=no,location=no,directories=no,status=no,menubar=no,scrollbars=yes,resizable=no,width=" + w + ",height=" + h; controlWindow=window.open(url,"",win); } &et=E0F54BF06C7306DC5EBB4958F19779A980C48B3C7C61A2422D6E95CBCECEA96244A2F2A11E7AC79EB81EE414F18EC2BE077C4DAFF8DEB852AAB3FE0F625BD4DB3250BA46188B1C8EE22536030564C483E2306C5659B5E73C550A1438DF3851E4D3978D68A4E03FD8A6B52FEA31182020B35C00A0D01881D75279E6FCDAB20A8C092675E11689A63D7B9F4670A108CC40CF24C0982D3097845408A515EDA28AA9F96C6A425F35C750CD384403DBA39C5E9AD0E79E38C979CFFD2D4F99E9C9D2621C5B47A106E60306D6A0A8EB7C5EF836578B83471DC10870&pcid=&cid=&jid=&yid=9475FABC7A03F4AB&aid=&vid=&iid=E158A972A605785F&sid=9D453329DCCABB94&eid=A58CF3BAE79427D0&fileno=20210245&flag=1&is_more=0">